FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level
Agustin Rodriguez and Dascher Pasco were published in Cannabis Business Executive for their article titled, “ FDA’s Draft Guidance for Clinical Research Regarding Cannabis and Cannabis Derivatives Takes a Firm Stance on the 0.3% THC Level.”
Our Cannabis Practice provides advice on issues related to applicable state law. Cannabis remains an illegal controlled substance under federal law.